Of the three Reuters-surveyed analysts covering SNY stock as of September 28, two have recommended a “hold,” and one has given it a “strong buy.” None of them have recommended a “sell,” despite its disappointing results in recent quarters.
Analysts’ consensus target price for SNY stock is $48.67, which implies an ~8.5% return based on SNY’s September 27 closing price of $44.84.
Analysts’ average target prices for peers Novo Nordisk (NVO), Eli Lilly (LLY), and GlaxoSmithKline (GSK) are $59.41, $99.53, and $43.06, respectively, implying 24.7%, -6.7%, and 6.3% returns over the next 12 months.
Analysts’ revisions and updates
On September 10, Bank of America Merrill Lynch updated its recommendation for SNY stock from “neutral” to “buy” and raised its target price from 80 euros to 95 euros. On September 7, Jefferies cut its target price for Sanofi to 76 euros.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!